Get started
Inhibikase Therapeutics, Inc.Inhibikase Therapeutics, Inc.Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

IKT chart


Full chart

IKT upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪266.75 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.72 USD
Net income (FY)
‪−19.03 M‬ USD
Revenue (FY)
‪260.50 K‬ USD
Shares float
‪51.26 M‬
Beta (1Y)
1.43

Employees


Employees (FY)
8
Change (1Y)
+2 +33.33%
Revenue / Employee (1Y)
‪32.56 K‬ USD
Net income / Employee (1Y)
‪−2.38 M‬ USD

About Inhibikase Therapeutics, Inc.


Sector
Health Technology
CEO
Milton H. Werner
Headquarters
Atlanta
Website
inhibikase.com
Founded
2008
FIGI
BBG005TP2339
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in developing protein kinase inhibitor therapeutics to modify the course of Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. It also focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. The company was founded by Milton H. Werner in September 2008 and is headquartered in Atlanta, GA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

IKT news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of IKT is 3.90 USD — it has increased by 11.20% in the past 24 hours. Watch Inhibikase Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Inhibikase Therapeutics, Inc. stocks are traded under the ticker IKT.
IKT stock has risen by 23.49% compared to the previous week, the month change is a 68.94% rise, over the last year Inhibikase Therapeutics, Inc. has showed a 174.30% increase.
We've gathered analysts' opinions on Inhibikase Therapeutics, Inc. future price: according to them, IKT price has a max estimate of 8.00 USD and a min estimate of 5.00 USD. Watch IKT chart and read a more detailed Inhibikase Therapeutics, Inc. stock forecast: see what analysts think of Inhibikase Therapeutics, Inc. and suggest that you do with its stocks.
IKT reached its all-time high on Dec 23, 2020 with the price of 70.79 USD, and its all-time low was 0.79 USD and was reached on Oct 10, 2023. View more price dynamics on IKT chart.
See other stocks reaching their highest and lowest prices.
IKT stock is 12.30% volatile and has beta coefficient of 1.43. Track Inhibikase Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Inhibikase Therapeutics, Inc. there?
Today Inhibikase Therapeutics, Inc. has the market capitalization of ‪266.75 M‬, it has increased by 24.06% over the last week.
Yes, you can track Inhibikase Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Inhibikase Therapeutics, Inc. is going to release the next earnings report on Mar 27, 2025. Keep track of upcoming events with our Earnings Calendar.
IKT earnings for the last quarter are −0.65 USD per share, whereas the estimation was −0.48 USD resulting in a −35.42% surprise. The estimated earnings for the next quarter are −0.09 USD per share. See more details about Inhibikase Therapeutics, Inc. earnings.
Inhibikase Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
IKT net income for the last quarter is ‪−5.78 M‬ USD, while the quarter before that showed ‪−4.96 M‬ USD of net income which accounts for −16.50% change. Track more Inhibikase Therapeutics, Inc. financial stats to get the full picture.
No, IKT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 18, 2024, the company has 8.00 employees. See our rating of the largest employees — is Inhibikase Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Inhibikase Therapeutics, Inc. EBITDA is ‪−20.04 M‬ USD, and current EBITDA margin is ‪−7.64 K‬%. See more stats in Inhibikase Therapeutics, Inc. financial statements.
Like other stocks, IKT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Inhibikase Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Inhibikase Therapeutics, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Inhibikase Therapeutics, Inc. stock shows the strong buy signal. See more of Inhibikase Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.